Please login to the form below

Not currently logged in
Email:
Password:

Vesicare

This page shows the latest Vesicare news and features for those working in and with pharma, biotech and healthcare.

Astellas sells dermatology unit to Leo for €675m

Astellas sells dermatology unit to Leo for €675m

The overarching aim is to prepare for the forthcoming patent expiries on big-selling drugs Vesicare (solifenacin succinate) for overactive bladder and cancer therapy Tarceva (erlotinib).

Latest news

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics